CASE WESTERN RESERVE UNIVERSITY
Highly selective targeted theranostics for prostate cancers
Highly selective targeted theranostics for prostate cancers is a funding opportunity from CASE WESTERN RESERVE UNIVERSITY, up to 634753, closing July 31, 2026.
Jul 31, 2026
(0d left)Overview
Abstract. Prostate cancer (PCa) is the most common malignancy and the second leading cause of cancer death in men in the United States. Although surgery and radiation therapy in patients with low risk disease appear appropriate and effective, those with high-risk localized disease almost always become hormone…